Monopar Therapeutics (NASDAQ:MNPR) Given Overweight Rating at Piper Sandler
Piper Sandler reaffirmed their overweight rating on shares of Monopar Therapeutics (NASDAQ:MNPR – Free Report) in a report released on Wednesday morning, Marketbeat.com reports. Piper Sandler currently has a $76.00 target price on the stock. Separately, HC Wainwright lifted their price target on Monopar Therapeutics from $22.00 to $40.00 and gave the company a “buy” […]
Piper Sandler reaffirmed their overweight rating on shares of Monopar Therapeutics (NASDAQ:MNPR – Free Report) in a report released on Wednesday morning, Marketbeat.com reports. Piper Sandler currently has a $76.00 target price on the stock. Separately, HC Wainwright lifted their price target on Monopar Therapeutics from $22.00 to $40.00 and gave the company a “buy” […]
